Search
Secretin human
go.drugbank.com/drugs/DB09532ApprovedInvestigationalPurified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S.. … Synthetic human secretin displays equivalent biological activity and properties as naturally-occurring secretin [A32265].
Cetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawn[A27143] It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and fungi. … [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]
Inosine pranobex
go.drugbank.com/drugs/DB13156ApprovedInosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
H3B-8800
go.drugbank.com/drugs/DB14017InvestigationalH3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. … It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalIt was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis. … [A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment.
Acetohexamide
go.drugbank.com/drugs/DB00414ApprovedWithdrawnAcetohexamide has been discontinued in the US market.
Tianeptine
go.drugbank.com/drugs/DB09289InvestigationalCurrently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in … Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946].
Obecabtagene autoleucel
go.drugbank.com/drugs/DB17362ApprovedInvestigational[L52450] Obecabtagene autoleucel was also investigated in other hematological cancers and systemic lupus erythematosus.[A265045] … [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Demeclocycline
go.drugbank.com/drugs/DB00618ApprovedA tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
Vilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone was given FDA approval on January 21, 2011[L6046,A177622].